Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2355-2364

  Mikkelsen, Marianne ^a   Holst, Peter Johannes ^a   Bukh, Jens ^a,b   Thomsen, Allan Randrup ^a   Christensen, Jan Pravsgaard ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD27 ANTIGEN; GAMMA INTERFERON; HEPATITIS C VACCINE; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 CHAPERONE PROTEIN INVARIANT CHAIN NONSTRUCTURAL PROTEIN 3 FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD27; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; VACCINIA VIRUS; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79951833033     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001877     Document Type: Article

References (49)

1. Shepard, C. W., L. Finelli, and M. J. Alter. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5: 558-567.
2. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
3. Afdhal, N. H. 2004. The natural history of hepatitis C. Semin. Liver Dis. 24 (Suppl 2): 3-8.
4. Bowen, D. G., and C. M. Walker. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952.
5. Diepolder, H. M., R. Zachoval, R. M. Hoffmann, E. A. Wierenga, T. Santantonio, M. C. Jung, D. Eichenlaub, and G. R. Pape. 1995. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346: 1006-1007.
6. Pape, G. R., T. J. Gerlach, H. M. Diepolder, N. Grüner, M. Jung, and T. Santantonio. 1999. Role of the specific T-cell response for clearance and control of hepatitis C virus. J. Viral Hepat. 6(Suppl 1): 36-40. (Pubitemid 29349787)
7. Aberle, J. H., E. Formann, P. Steindl-Munda, L. Weseslindtner, C. Gurguta, G. Perstinger, E. Grilnberger, H. Laferl, H. P. Dienes, T. Popow-Kraupp, et al. 2006. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J. Clin. Virol. 36: 24-31.
8. Thimme, R., D. Oldach, K. M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194: 1395-1406.
9. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191: 1499-1512.
10. Shoukry, N. H., A. Grakoui, M. Houghton, D. Y. Chien, J. Ghrayeb, K. A. Reimann, and C. M. Walker. 2003. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197: 1645-1655.
11. Grakoui, A., N. H. Shoukry, D. J.Woollard, J. H. Han, H. L. Hanson, J. Ghrayeb, K. K. Murthy, C. M. Rice, and C. M. Walker. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662.
12. Bukh, J., R. Thimme, J. C. Meunier, K. Faulk, H. C. Spangenberg, K. M. Chang, W. Satterfield, F. V. Chisari, and R. H. Purcell. 2008. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82: 8183-8195.
13. Kristensen, N. N., J. P. Christensen, and A. R. Thomsen. 2002. High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development. J. Gen. Virol. 83: 2123-2133.
14. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78: 5535-5545.
15. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
16. Mikkelsen, M., and J. Bukh. 2007. Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead. Curr. Infect. Dis. Rep. 9: 94-101.
17. Wedemeyer, H., S. Gagneten, A. Davis, R. Bartenschlager, S. Feinstone, and B. Rehermann. 2001. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121: 1158-1166. (Pubitemid 33022096)
18. Frelin, L., G. Ahlén, M. Alheim, O. Weiland, C. Barnfield, P. Liljeström, and M. Sällberg. 2004. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther. 11: 522-533. (Pubitemid 38443519)
19. Martin, P., P. Parroche, L. Chatel, C. Barretto, A. Beck, C. Trépo, C. Bain, Y. C. Lone, G. Inchauspé, and A. Fournillier. 2004. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. J. Med. Virol. 74: 397-405.
20. Lin, Y., T. Kwon, J. Polo, Y. F. Zhu, S. Coates, K. Crawford, C. Dong, M. Wininger, J. Hall, M. Selby, et al. 2008. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J. Virol. 82: 7492-7503.
21. Folgori, A., S. Capone, L. Ruggeri, A. Meola, E. Sporeno, B. B. Ercole, M. Pezzanera, R. Tafi, M. Arcuri, E. Fattori, et al. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12: 190-197.
22. Diepolder, H. M., J. T. Gerlach, R. Zachoval, R. M. Hoffmann, M. C. Jung, E. A. Wierenga, S. Scholz, T. Santantonio, M. Houghton, S. Southwood, et al. 1997. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71: 6011-6019. (Pubitemid 27304939)
23. Schulze zur Wiesch, J., G. M. Lauer, C. L. Day, A. Y. Kim, K. Ouchi, J. E. Duncan, A. G. Wurcel, J. Timm, A. M. Jones, B. Mothe, et al. 2005. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J. Immunol. 175: 3603-3613.
24. Bukh, J., R. H. Miller, and R. H. Purcell. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15: 41-63.
25. Tatsis, N., and H. C. Ertl. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10: 616-629.
26. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replicationin-competent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335. (Pubitemid 34087555)
27. Santra, S., Y. Sun, B. Korioth-Schmitz, J. Fitzgerald, C. Charbonneau, G. Santos, M. S. Seaman, S. J. Ratcliffe, D. C. Montefiori, G. J. Nabel, et al. 2009. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27: 5837-5845.
28. Holst, P. J., M. R. Sorensen, C. M. Mandrup Jensen, C. Orskov, A. R. Thomsen, and J. P. Christensen. 2008. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol. 180: 3339-3346.
29. Yanagi, M., M. St Claire, M. Shapiro, S. U. Emerson, R. H. Purcell, and J. Bukh. 1998. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244: 161-172. (Pubitemid 28384135)
30. Becker, T. C., R. J. Noel, W. S. Coats, A. M. Gomez-Foix, T. Alam, R. D. Gerard, and C. B. Newgard. 1994. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43: 161-189.
31. Holst, P. J., C. Ørskov, A. R. Thomsen, and J. P. Christensen. 2010. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J. Immunol. 184: 4431-4439.
32. Hermans, I. F., J. D. Silk, J. Yang, M. J. Palmowski, U. Gileadi, C. McCarthy, M. Salio, F. Ronchese, and V. Cerundolo. 2004. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285: 25-40. (Pubitemid 38186583)
33. Eisenbach, C., A. Freyse, C. M. Lupu, K. Weigand, E. Ernst, B. Hoyler, W. Stremmel, J. J. Bugert, and J. Encke. 2006. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse. Vaccine 24: 5140-5148. (Pubitemid 43818198)
34. Wiesel, M., S. Walton, K. Richter, and A. Oxenius. 2009. Virus-specific CD8 T cells: activation, differentiation and memory formation. APMIS 117: 356-381.
35. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1: 433-440.
36. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198.
37. Ochsenbein, A. F., S. R. Riddell, M. Brown, L. Corey, G. M. Baerlocher, P. M. Lansdorp, and P. D. Greenberg. 2004. CD27 expression promotes longterm survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200: 1407-1417.
38. Wherry, E. J., V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
39. Ahlers, J. D., and I. M. Belyakov. 2010. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115: 1678-1689.
40. Grujic, M., P. J. Holst, J. P. Christensen, and A. R. Thomsen. 2009. Fusion of a viral antigen to invariant chain leads to augmented T-cell immunity and improved protection in gene-gun DNA-vaccinated mice. J. Gen. Virol. 90: 414-422.
41. Lasaro, M. O., N. Tatsis, S. E. Hensley, J. C. Whitbeck, S. W. Lin, J. J. Rux, E. J. Wherry, G. H. Cohen, R. J. Eisenberg, and H. C. Ertl. 2008. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med. 14: 205-212.
42. Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effect or functions. Nature 401: 708-712.
43. Hikono, H., J. E. Kohlmeier, S. Takamura, S. T. Wittmer, A. D. Roberts, and D. L. Woodland. 2007. Activation phenotype, rather than central- or effect or memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med. 204: 1625-1636.
44. Golden-Mason, L., J. R. Burton, Jr., N. Castelblanco, J. Klarquist, S. Benlloch, C. Wang, and H. R. Rosen. 2006. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 44: 1098-1109.
45. Grujic, M., C. Bartholdy, M. Remy, D. D. Pinschewer, J. P. Christensen, and A. R. Thomsen. 2010. The role of CD80/CD86 in generation and maintenance of functional virus-specific CD8+ T cells in mice infected with lymphocytic choriomeningitis virus. J. Immunol. 185: 1730-1743.
46. Appay, V., P. R. Dunbar, M. Callan, P. Klenerman, G. M. Gillespie, L. Papagno, G. S. Ogg, A. King, F. Lechner, C. A. Spina, et al. 2002. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
47. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science 259: 1742-1745. (Pubitemid 23114659)
48. Bachmann, M. F., P. Wolint, K. Schwarz, P. Jäger, and A. Oxenius. 2005. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J. Immunol. 175: 4686-4696. (Pubitemid 41362010)
49. Castellino, F., and R. N. Germain. 2007. Chemokine-guided CD4+ T cell help enhances generation of IL-6RalphahighIL-7Ralpha high prememory CD8+ T cells. J. Immunol. 178: 778-787.